Introduction {#s1}
============

Coronary artery bypass grafting (CABG) has quickly advanced to one of the most frequently performed surgical procedures.^[@B1])^ It is the most effective coronary revascularization method in severe coronary artery disease, which remains a leading cause of death in the Western countries.^[@B2])^ Despite excellent short-term outcomes, long-term results of CABG remain dependent on the selection of graft conduits used. Although the recent long-term results from important trials showed significantly better survival rates after CABG than after percutaneous coronary intervention (PCI), CABG rates are declining over the past years, while PCI rates increase accordingly.^[@B3],[@B4])^ Nonetheless, CABG remains the gold standard for patients with coronary artery disease including those with diabetes and/or complex left main or three-vessel disease.^[@B4])^

The benefits of left internal thoracic artery (LITA) to left anterior descending coronary artery (LAD) grafting are well established and explain its common implementation in surgical practice. However, the choice of a second graft remains a considerable source of debate.^[@B5],[@B6])^

There is robust evidence accumulating in favor of the radial artery (RA) as a second arterial graft, indicating superior patency rates and improved intermediate and long-term outcomes in comparison with venous grafts.^[@B7],[@B8])^ However, the use of the RA is still limited to \<13% of all CABG operations.^[@B9])^

The purpose of this study is to assess long-term outcome of all-arterial CABG using the LITA and RA in T-Graft configuration and to evaluate survival benefit in a propensity-score matched comparison with combined venous and arterial bypass grafting using a single ITA and saphenous veins.

Methods {#s2}
=======

In this study, we selected patients who underwent their first non-emergent CABG for left-main or double- and triple-vessel coronary artery disease at our center from January 2002 to August 2004. Patients were study-eligible if they received either total arterial revascularization (TAR) with LITA and RA grafting in T-graft configuration or aortocoronary venous bypass (ACVB) in combination with arterial grafts using either the LITA or right internal thoracic artery (RITA) and saphenous vein grafts as complementing conduit.

For follow-up, patients were contacted to investigate subjective symptoms (New York Heart Association (NYHA), Canadian Cardiovascular Society \[CCS\]), survival, incidence of adverse events (stroke, myocardial infarction \[MI\]), and re-interventions (PCI, CABG) since the surgical procedure.

Pre-, peri-, and postoperative data were retrospectively acquired through the hospital's internal database or obtained by contacting the patient's cardiologist or general practitioner.

Mortality data were crosschecked with the respective Citizens Registration Office.

The follow-up time ranged from the date of the operation until the verified date of death or last date of contact.

All patients signed informed consent for data collection and processing at the time of consent for the surgical procedure.

Surgical Technique {#s3}
==================

For the ACVB group: The saphenous vein was harvested in parallel to the median sternotomy followed by the harvest of the ITA in a pedicled fashion and irrigation with papaverine. Subsequently, heparinization (300 U/kg) and cardiopulmonary bypass initiation followed in standard fashion. We used the thoracic internal artery as a bypass graft for the LAD (or, if necessary a diagonal branch) in situ. The saphenous vein was used for as many bypass grafts as necessary.

For the TAR group: Upon full median sternotomy, the ITA was harvested in a pedicled fashion and was irrigated with papaverine solution. Duplex sonography was performed to assure palmar perfusion via the ulnar artery prior to harvesting the RA from the non-dominant arm. The performance of the T-anastomosis between the LITA and the RA occurred prior to initiating cardiopulmonary bypass with 8--0 prolene sutures. The T-anastomosis was carefully placed within the pericardium. Upon completion of the T-graft the heparinization (300 U/kg) and cardiopulmonary bypass initiation followed according to standard fashion. Intermittent antegrade cold-blood cardioplegia or crystalloid cardioplegia was used for myocardium protection. If heparin was given to keep the activated clotting time above 450 seconds, protamine was administered at the end of the surgical procedure. If possible, intravenous nitroglycerin infusions were administered for the first 24 hours. Six hours postoperatively, 300 mg of aspirin was given i.v. If not contraindicated, 100 mg of aspirin p.o., cholesterol-lowering agents, and β-blockers were administered daily.

Statistical Analysis and Propensity Score Matching {#s4}
==================================================

Normally distributed metric data were analyzed using the student's t Test and non-normally distributed metric or ordinal data were analyzed using the Mann--Whitney test. The Shapiro--Wilk test was used to test for normality. The Fisher-Exact Test was used for 2 × 2 contingency tables; other contingency tables were tested by chi-square test.

The association of covariates on overall survival was tested on the entire study population, while the effect of group (TAR vs. ACVB) on survival was tested among propensity-matched cohorts. Each confounder was tested using the Cox proportional hazard regression. Confounders with a *P* value of \<0.1 were comprised in the multivariable model selected by forward selection (likelihood ratio) method. Hazard ratios (HR) were assessed for every variable.

Kaplan--Meier functions were used to plot postoperative survival. A log-rank test, stratified by the propensity- matched pairs, was used to assess the equality of survivor functions.

The TAR and ACVB groups showed significant risk factor and demographic differences. To balance the impact of treatment selection and confounders in this retrospective observational study, propensity-score matching was performed. It has shown to render unbiased assessment of treatment effects even in small study samples as long as accurate confounders are included in the matching.^[@B10])^

The following confounders turned out to be significant in the previous univariate survival analysis and were considered for matching: Gender, age, body mass index (BMI), hyperlipidemia, non-insulin-dependent diabetes mellitus (DM), peripheral arterial occlusive disease (PAOD), chronic obstructive pulmonary disease (COPD), pulmonary hypertension, glomerular filtration rate (GFR), NYHA class (Groups: I + II, III + IV), EuroSCORE (%), previous PCI, LAD stenosis, right coronary artery (RCA) stenosis, urgent operation, graft count and cross-clamp, and bypass times.

The propensity-score was derived by logistic regression with 1:1 matching using the nearest-neighbor method with a caliper width of 0.2 of the standard deviation (SD) of the logit of the propensity score.

To ensure proper balance among the groups, a comparison of SDs, means, and proportions of baseline demographic characteristics was performed. The Mann--Whitney test, the student's t-test and the χ^2^ test validated statistical significance for continuous and categorical variables.

A *P* value of \<0.05 was considered significant. Continuous variables were expressed as mean ± SD and categorical variables as total number (*n*) and percentages (%). The hazard rate and the 95% confidence range complemented confounders. IBM's SPSS Statistics Version 24 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

Results {#s5}
=======

Baseline and operative characteristics {#s5-1}
--------------------------------------

We analyzed 345 patients who fulfilled the inclusion criteria. Both groups showed substantial differences in demographic and risk factors (**[Table 1](#table1){ref-type="table"}**). Reflecting a practice selection, patients receiving TAR were younger (62.1 ± 8.45 years vs. 68.6 ± 7.12 years, *P* \<0.001), showed lower Euroscores (2.82 ± 3.11% vs. 4.74 ± 5.57%, *P* \<0.001) and were less likely to have impaired renal function, pulmonary hypertension, and left main coronary disease. The TAR group had proportionally less females than the ACVB group (9.6% vs. 19.6%, *P* = 0.009). In patients receiving TAR, operative urgency was more likely to be non-urgent (86.6% vs. 61.4%, *P* \<0.001) and NYHA classes I-II applied more frequently (47.6% vs. 11.4%, *P* \<0.001). Left ventricular function showed no statistically significant difference between the two cohorts (58% vs. 57.3%, *P* = 0.673). Both groups were comparable for pre-treatment characteristics after matching of 81 patient pairs (**[Table 2](#table2){ref-type="table"}**).

###### Baseline characteristics in unmatched cohorts

                                           TAR (n = 187)   ACVB (n = 158)                 
  ---------------------------------------- --------------- ---------------- ------ ------ -----------
  Age (years)                              62.1            8.45             68.6   7.12   \<0.001
  GFR (mL/min)                             98              30.5             78.7   30.3   \<0.001
  Euroscore (%)                            2.82            3.11             4.74   5.57   \<0.001
  Left main disease (%)                    14.2            24.3             27.8   35.1   \<0.001
  BMI                                      27.6            3.98             26.9   3.29   0.077
  Left ventricular ejection fraction (%)   58              13.0             57.3   14.5   0.673
                                                                                          
                                           n               (%)              n      (%)    *P* value
                                                                                          
  Gender                                                                                  
   Female                                  18              9.6              31     19.6   0.009
   Male                                    169             90.4             127    80.4   
  Arterial hypertension                    152             81.3             115    72.8   0.071
  Hyperlipidemia                           135             72.2             110    69.6   0.635
  DM                                                                                      
   Non-insulin-dependent                   52              27.8             44     27.8   1.000
   Insulin-dependent                       20              10.7             20     12.7   0.615
  PAOD                                     37              19.8             27     17.1   0.579
  COPD                                     26              13.9             15     9.5    0.244
  Pulmonary hypertension                   13              7                2      1.3    0.014
  Extent of coronary vessel disease                                                       
   Two-vessel disease                      21              11.2             16     10.1   0.862
   Three-vessel disease                    166             88.8             138    87.3   0.740
  Left ventricular ejection fraction                                                      
   Mild (45--54%)                          31              22.3             25     18.5   0.307
   Moderate (30--44%)                      12              8.6              20     14.8   
   Severe (\<30%)                          2               1.4              4      3.0    
  Previous MI \<90 days                    36              19.3             24     15.2   0.393
  Previous PCI                             32              17.1             28     17.9   0.887
  Previous cardiac surgery                 8               4.3              12     7.6    0.248
  NYHA status                                                                             
   I-II                                    89              47.6             18     11.4   \<0.001
   III-IV                                  98              82.4             140    88.6   
  CCS class of angina                                                                     
   No angina                               12              6.4              4      2.5    0.083
   I-II                                    63              33.7             44     27.8   
   III-IV                                  112             59.9             110    69.6   
  Operative urgency                                                                       
   Non-urgent                              161             86.6             97     61.4   \<0.001
   Urgent                                  25              13.4             61     38.6   

ACVB: combined arterial and venous bypass; BMI: body mass index; CCS: Canadian Cardiovascular Society; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; GFR: glomerular filtration rate; MI: myocardial infarction; NYHA: New York Heart Association; PAOD: peripheral arterial occlusive disease; PCI: previous coronary intervention; SD: standard deviation; TAR: total arterial revascularization

###### Baseline characteristics in propensity-score-matched cohorts

                               TAR (n = 81)   ACVB (n = 81)                 
  ---------------------------- -------------- --------------- ------ ------ -----------
  Age (years)                  66.1           6.97            66.3   6.87   0.847
  BMI                          27.1           3.85            26.9   2.79   0.760
  GFR (mL/min)                 87.9           22.2            88.2   25.5   0.932
  Euroscore (%)                2.89           2.33            2.91   1.96   0.351
  LAD stenosis (%)             76.1           24.9            75.9   25     0.970
  RCA stenosis (%)             24             36.1            26.3   39     0.761
  PLA1 stenosis (%)            68             33.5            71.4   32.2   0.470
                                                                            
                               n              (%)             n      (%)    *P* value
                                                                            
  Gender                                                                    
   Female                      11             13.6            9      11.1   0.812
   Male                        70             86.4            72     88.9   
  Hyperlipidemia               58             71.6            56     69.1   0.864
  DM (non-insulin-dependent)   21             25.9            23     28.4   0.860
  PAOD                         12             14.8            14     17.3   0.831
  COPD                         8              9.9             6      7.4    0.781
  Pulmonary hypertension       0              0               0      0      
  Three-vessel disease         71             87.7            74     91.4   0.609
  Previous PCI                 17             21              14     17.3   0.690
  Previous cardiac surgery     3              3.7             2      2.5    1.000
  NYHA status                                                               
   I-II                        18             22.2            17     21     1.000
   III-IV                      63             77.8            64     79     
  Operative urgency                                                         
   Non-urgent                  61             75.3            58     71.6   0.722
   Urgent                      20             24.7            23     28.4   

ACVB: combined arterial and venous revascularization; BMI: body mass index; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; GFR: glomerular filtration rate; LAD: left anterior descending; NYHA: New York Heart Association; PAOD: peripheral arterial occlusive disease; PCI: previous coronary intervention; PLA: posterior lateral branch; RCA: right coronary artery; SD: standard deviation; TAR: total arterial revascularization

Within the TAR group, 187 (100%) patients received a RA grafted to the 187 LITAs (100%) in T-graft configuration. The 158 patients in the ACVB group received either a single (5.7%) or two and more (94.3%) venous grafts to supplement 156 LITAs (98.7%) and 2 RITAs (1.3%). In total, a mean of 3.29 ± 0.7 RA and 3.63 ± 0.82 ACVB distal anastomoses was performed. Further operative characteristics are displayed in **[Table 3](#table3){ref-type="table"}**.

###### Operative characteristics and early outcomes in unmatched cohorts

                                    TAR (n = 187)   ACVB (n = 158)                 
  --------------------------------- --------------- ---------------- ------ ------ -----------
  Operation time (min)              183             29.2             200    61.8   0.002
  Bypass time (min)                 67.3            17.6             97.1   45     \<0.001
  Cross-clamp time                  40.5            12               50.9   17.7   \<0.001
  Peripheral anastomoses (count)    3.29            0.7              3.62   0.75   \<0.001
  Ventilation time (h)              20.5            86.8             23.9   37.1   \<0.001
  Stay on ICU (days)                1.73            4.11             2.16   2.46   \<0.001
  Total hospital stay (days)        13.5            7.39             15.1   7.48   0.044
  Follow-up time (years)            13.1            0.86             13.6   0.15   \<0.001
                                                                                   
                                    n               (%)              n      (%)    *P* value
                                                                                   
  Conduits used                                                                    
   Venous                                                                          
    1                               0               0                9      5.7    \<0.001
    2                               0               0                128    81     \<0.001
    3                               0               0                21     13.3   \<0.001
   Arterial                                                                        
    1                               0               0                158    100    \<0.001
    2                               187             100              0      0      \<0.001
  Harvested grafts                                                                 
   LITA                             187             100              156    93.7   \<0.001
   RITA                             0               0                2      1.3    \<0.001
   RA                               187             100              0      0      \<0.001
   SV                               0               0                158    100    \<0.001
  Conduits to                                                                      
   LAD                              185             98.9             154    97.5   0.419
   Diagonal                         86              46               84     53.2   0.196
   RCx                              4               2.1              2      1.3    0.691
   PLA1                             128             68.4             124    78.5   0.039
   PLA2                             41              21.9             33     20.9   0.895
   PLA3                             3               1.6              8      5.1    0.121
   RIM                              20              10.7             23     14.6   0.327
   RCA                              5               2.7              19     12     \<0.001
   RPLA                             27              14.4             21     13.3   0.876
   RIVP                             113             60.4             97     61.4   0.912
  SAE                                                                              
   Cardiopulmonary resuscitation    5               2.7              4      2.5    1.000
   Myocardial infarction            3               1.6              3      1.9    1.000
   Low cardiac output               3               1.6              9      5.7    0.073
   Neurological complications       8               4.3              4      2.5    0.557
   Renal failure                                                                   
    GFR (ml/min) \<60               16              8.6              40     26.3   \<0.001
    GFR (mL/min) \<30               2               1.1              14     9.2    \<0.001
   Deep sternal infection           1               0.5              5      3.2    0.097
   Harvesting site infection        2               1.1              7      4.4    0.086
   Prolonged ventilation (\>48 h)   5               2.7              6      3.8    0.557
  Post-OP death within 30 days      0               0                7      4.5    0.004

ACVB: combined arterial and venous revascularization; GFR: glomerular filtration rate; ICU: intensive care unit; LAD: left anterior descending; LITA: left internal thoracic artery; PLA: posterior lateral branch; RA: radial artery; RCA: right coronary artery; RCx: left circumflex; RIM: ramus intermedius; RITA: right internal thoracic artery; RIVP: right posterior descending; RPLA: right posterior lateral branch; SAE: serious adverse event; SD: standard deviation; SV: saphenous vein; TAR: total arterial revascularization

More importantly, patients receiving TAR experienced significantly shorter operation times (183 ± 29.2 min vs. 200 ± 61.8 min, *P* = 0.002), cardiopulmonary bypass times (20.5 ± 86.6 h vs. 23.9 ± 37.1 h, *P* \<0.001), aortic cross-clamp times (40.5 ± 12 min vs. 50.9 ± 17.7 min, *P* \<0.001), and ventilation times (67.3 ± 17.6 min vs. 97.1 ± 45 min, *P* \<0.001). Also, hospital and intensive care unit stays were significantly shorter in the TAR group.

Outcomes {#s6}
========

Early postoperative incidence of adverse events such as MIs, neurological complications (stroke, transient ischemic attack \[TIA\]), deep sternal wound infections, respective harvesting site infections, and prolonged ventilation (\>48h) was not statistically different in both groups. However, renal impairment and death (within 30 days) occurred less frequently in patients receiving TAR (1.1 % vs. 9.2%, *P* \<0.001 and 0% vs. 4.5%, *P* = 0.004, respectively) (**[Table 3](#table3){ref-type="table"}**).

In univariate analysis, age, DM, PAOD, COPD, GFR, NYHA class, pulmonary hypertension, EuroSCORE, RCA stenosis, urgency of operation, graft count and cross-clamp, and bypass times were significant negative factors for survival. In contrast, male gender, BMI (cutoff value = 25), hyperlipidemia, previous PCI, and LAD stenosis seemed to be protective from mortality. Multivariate analysis using Cox proportional hazard regression with forward selection (likelihood ratio) method demonstrated that only previous PCI and cross-clamp time as independent factors negatively impacted survival.

Follow-up was slightly shorter in the TAR group (13.1 ± 0.86 years vs. 13.6 ± 0.15 years, *P* \<0.001). The occurrence of stroke or TIA, MIs, and coronary re-interventions (CABG or PCI) in the long-term follow-up of the unmatched cohorts was comparable (**[Table 4](#table4){ref-type="table"}**). Cardiovascular disease, the leading cause of death in both groups, was proportionally more frequent in the ACVB group (22.8% vs. 12.3%). Patients receiving TAR showed distinctly superior long-term survival (12.5 ± 0.32 years vs. 10.2 ± 0.42 years, *P* \<0.001) (**[Table 4](#table4){ref-type="table"}**). Most notably, group affiliation did not alter this observation among propensity-score matched patients (**[Fig. 1](#F1){ref-type="fig"}**): Patients receiving TAR exhibited improved survival (12.7 ± 0.41 years vs. 11.3 ± 0.45 years, *P* = 0.017) among the matched pairs. Additionally, Cox regression confirmed that TAR group affiliation protected from late mortality (HR 0.541, 95% CI: 0.324--0.904, *P* = 0.017).

###### Follow-up in unmatched cohorts

                               TAR (n = 128)   ACVB (n = 105)                 
  ---------------------------- --------------- ---------------- ------ ------ -----------
  Follow-up time (years)       13.1            0.86             13.6   0.15   \<0.001
  Long-term survival (years)   12.5            0.32             10.2   0.42   \<0.001
                                                                              
                               n               (%)              n      (%)    *P* value
                                                                              
  Apoplex                      17              13.3             8      7.6    0.204
  Myocardial infarction        14              10.9             15     14.3   0.550
  PCI                          24              18.8             18     17.1   0.864
  Coronary bypass operation    3               2.3              2      1.9    1.000
  NYHA status                                                                 
   I-II                        95              74.2             76     63.8   0.058
   III-IV                      33              25.8             38     36.2   
  CCS class of angina                                                         
   No angina                   2               1.6              26     24.8   \<0.001
   I-II                        119             93               64     61     
   III-IV                      7               5.5              15     14.3   

  -------------------------- ---- ------ ---- ------
  Cause of death                              
   Cardiovascular diseases   7    12.3   21   22.8
   Cancer                    5    8.5    5    5.4
   Sepsis/Inflammation       5    8.8    2    2.2
   Stroke                    3    5.3    2    2.2
   Acute renal failure       2    3.5    1    1.1
   Multiorgan dysfunction    0    0      3    3.3
   Trauma                    2    3.5    1    1.1
   Hemorrhage                0    0      1    1.1
   Other causes              0    0      1    1.1
   Unknown cause             33   57.9   55   59.8
  -------------------------- ---- ------ ---- ------

ACVB: combined arterial and venous revascularization; CCS: Canadian Cardiovascular Society; NYHA: New York Heart Association; PCI: previous coronary intervention; SD: standard deviation; TAR: total arterial revascularization

![Overall survival in the propensity-matched cohort by type of conduit. ACVB: combined arterial and venous revascularization; TAR: total arterial revascularization](atcs-26-030-g001){#F1}

Discussion {#s7}
==========

In our study, we were able to show that TAR is superior to the combined venous and arterial approach. During the early days of TAR, this approach was reserved for healthier patients and performed by more skilled surgeons. Over the time, this policy has changed, and TAR is now a standard operation, taught to our surgeons from the beginning of their career. Primarily, we aim to choose TAR and only resort to using venous grafts as an alternative if respective contraindications exist.

In some centers, concerns over its vasospastic tendencies, its technical challenge, and the necessity of bypassing severe stenosis (\>70%) to avoid a reduction in conduit patency have limited the adoption of RA grafting.^[@B11],[@B12])^

However, apart from its recognized superior patency rates over venous grafts,^[@B7],[@B13]--[@B15])^ numerous anatomo-pathological characteristics have been reported that qualify the RA as a suitable conduit for CABG: its resistance to atherosclerosis, adaption to high arterial pressure, its convenient site allowing parallel LITA harvesting, caliber size and length, and the considerable muscular wall enabling easy handling.^[@B16])^ These promising qualities are in sharp contrast to the persistent reluctance of surgeons towards its extended use in TAR.

The main finding of our study is that multiple arterial grafting using a LITA and RA as a composite T-graft was associated with superior long-term survival compared to a combination of ITA and venous grafting. Despite the smaller likelihood of death due to cardiac-related causes, use of TAR did not derive a positive impact on long-term complications and events such as MI, stroke, TIA, and re-interventions.

Our results are consistent with other studies that have alluded to improved survival when using the RA in multiple arterial grafting.^[@B17]--[@B19])^

Buxton and colleagues validated the association of TAR using the LITA and RA with improved long-term survival benefit compared to ACVB in a propensity- matched cohort study after 15 years of follow-up (54% ± 3.3% vs. 41% ± 3.0%, *P* = 0.0004).^[@B20])^

Another large cohort study conducted by Schwann et al. investigated propensity-matched patients undergoing non-salvage primary CABG at two institutions. The authors found ITA and RA grafting to be associated with significantly better cumulative mortality rates compared to ITA and saphenous vein grafting.

Similarly, Goldstone et al. reported a significantly lower mortality rate in patients receiving arterial grafts in multivessel CABG compared to venous grafts. Additionally, the authors showed that the RITA led to an increase in sternal wound infections and that it offered no benefit over the use of the RA.^[@B21])^

Our results are at odds with studies that have investigated the impact of RA use on survival in distinct subgroups of patients. Hayward and colleagues reported similar survival rates between propensity-matched RA and venous groups after 7 years of follow-up in high-risk patients (RA: 75 ± 2.6% vs. Veins: 74 ± 2.9%, *P* = 0.65).^[@B22])^

Another study has alluded to a limited use of the RA as a second arterial conduit since a gradual decline of survival benefit was observed with increasing age. Patients older than 70 years no longer presented with improved survival (adjusted HR 0.90, 95% CI: 0.63--1.28, *P* = 0.57).^[@B23])^

The use of the RA as a T-graft remains under discussion. The RA can be used either as a free graft (directly to the aorta) or as a Y- or T-graft (anastomosed to the LITA or RITA) as a composite graft. Whereas long-term outcomes between these two techniques seem to be comparable, some surgeons are hesitant when it comes to the use of a single composite T-graft due to concerns regarding inferior long-term patency rates in comparison with multiple singular grafts. We do, however, believe that the use of the RA as a T-graft results in several advantages. It may be beneficial in preventing neurological events in patients with severe calcification of the ascending aorta since additional aortic side-clamping is unnecessary. Also, the use of the RA as a T-graft provides sufficient conduit length which usually enables the performance of up to four sequential anastomoses. Therefore, even in complex cases, a complete revascularization may be performed with only two bypass grafts. Also, RA anastomeses made to the ascending aorta can be prone to develop fibrous intimal hyperplasia due to the enormous aortic wall stress.^[@B7])^ Besides, the limited use of two grafts during the initial surgical revascularization allows the harvest of further grafts in the case of a necessary surgical re-intervention.

A possible drawback that remains with the concept of composite grafts is the dependency of distal anastomoses perfusion on a single inflow (LITA or RITA). Even though Affleck et al. showed sufficient flow reserve of the T-graft to meet cardiac demand,^[@B24])^ Jung et al. showed better patency rates for the direct aortic anastomosis when comparing direct aortic anastomosis of the RA and anastomosis to the LITA.^[@B25])^ However, these results were questioned by other groups that found no difference between these surgical techniques.^[@B26],[@B27])^ Jung et al. argued that direct RA--aortic anastomosis might lead to an ameliorated RA flow due to higher aortic driving pressure compared to the composite graft.

Additionally, RA patency rates have shown to be greatly impacted by target vessel characteristics such as anastomosis site as well as level of stenosis within the bypassed artery.^[@B28])^ Whereas the use of RA grafts to the LAD or the circumflex has shown to yield encouraging results, Nakajima et al. have shown higher risk rates for anastomotic failure in RCA anastomosis targets, especially in branch locations that have shown to be moderately stenosed.^[@B29])^ Given overall higher patency rates, we do believe in strategic implication of the RA in RCA targets that show high stenosis. With respect to flow dynamic in the bypassed moderately stenosed RCA targets, other conduits may show superior performance.

There are certain questions raised by our data that need to be addressed in future studies. As mentioned, MI, stroke, TIA, and re-interventions did not differ between the groups. Also, the relatively high incidence of stroke during follow-up needs to be addressed further. Especially in relation to the occurrence of atrial fibrillation, the resection of the left atrial appendage as a standard in operative revascularization should be discussed.

Study limitations {#s7-1}
-----------------

Our findings are based on a retrospective analysis of observational single-center data, which could restrict their transferability. We have implemented propensity score matching to estimate causal treatment effects in a comparatively small study cohort; therefore, effects of unmeasured covariates cannot be ruled out.

Conclusions {#s8}
===========

In view of our results, the RA should be considered more frequently as a composite to the LITA in all-arterial revascularization. Our analysis supports the hypothesis that it could project better long-term survival onto the greater population undergoing CABG.
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